Company: CNTB
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001835268-25-000058
Chunk: 9

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 9
---
 9,009 26,516 23,020 General and administrative expense6,583 6,056 16,096 15,148 Total operating expenses17,693 15,065 42,612 38,168 Loss from operations(17,677)(13,846)(42,548)(12,833)Other income, net:Interest income545 1,135 1,884 3,604 Other income (expense)(7)(108)463 2,624 Total other income, net538 1,027 2,347 6,228 Net loss before income tax(17,139)(12,819)(40,201)(6,605)Income tax expense61 57 170 117 Net loss$(17,200)$(12,876)$(40,371)$(6,722)Other comprehensive loss:Foreign currency translation adjustments87 570 385 415 Unrealized gains on available-for-sale investments11 — 4 11 Comprehensive loss$(17,102)$(12,306)$(39,982)$(6,296)Basic and diluted net loss per ordinary share$(0.31)$(0.23)$(0.73)$(0.12)Weighted-average ordinary shares outstanding, basic and diluted55,716 55,254 55,523 55,181 

See accompanying notes.

5

TABLE OF CONTENTS

CONNECT BIOPHARMA HOLDINGS LIMITED

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(Unaudited)

(in thousands)

Ordinary SharesAdditional Paid-In CapitalAccumulated Other Comprehensive LossTreasuryAccumulatedDeficitTotal Shareholders' EquitySharesAmountSharesBalance, December 31, 202455,349$10 $439,357 $(1,666)$(180)$(345,355)$92,166 Issuance of ordinary shares upon exercise of stock options3 — 2 — — — 2 Share-based compensation expense— — 942 — — — 942 Net loss— — — — — (10,272)(10,272)Net unrealized losses on available-for-sale investments— — — (1)— — (1)Foreign currency translation adjustments— — — 62 — — 62 Balance, March